Episode 101: Target doses for CHF – is there collateral damage when shooting for targets?
In episode 101, your friendly centurions, James and Mike, take a shot at the evidence around target doses for drugs in CHF and find the data is not as compelling as one might think. They discuss the approach of making sure we don’t cause side effects trying to get patients to these targets. To prove the point, we both took high doses of ACE inhibitors, ARBs, and beta-blockers at the beginning of the podcast and the recording results clearly demonstrate the harm that can occur from arbitrary use of high doses of medications.
Show notes
1) Getting to carvedilol doses
2) Network – ACE doses
3) ATLAS – ACE doses
4) Carvedilol doses
4) Beta-blocker doses
Ann Intern Med 2009;150:784-94
5) HEAAL – losartan
